Council of Economic Advisers. Savings from Most-Favored-Nation (MFN) drug pricing policy. Washington (DC): Executive Office of the President; 2026 May 5. […]
Ramagopalan SV, Ryan ML. Most-Favored-Nation pricing meets Joint Clinical Assessment: early evidence of compounding pressure on European drug launches. J
Cross S, Claxton K, Hill A. Health costs of the UK-US trade deal on pharmaceuticals. BMJ. 2026;394:e340588. Geopolítica: un
Kirson NY, Dooley JM, Ge Z, Chandra A. Taking stock of most-favored nation deals: how have markets reacted? Health Aff
Rebitzer JB, Rebitzer RS. Why not better and cheaper? Healthcare and innovation. Oxford: Oxford University Press; 2023 El cuarto
Vallejo-Torres L, Edney LC, Espinosa O, Karnon J, Longo F, Paulden M, Howdon D, Vanness DJ. Politicised Changes to the
